Xiaoyu Hu

机构：Johns Hopkins University, Shandong University, Shandong Tumor Hospital, Huizhou Central People's Hospital, Shandong First Medical University, Chengdu University of Traditional Chinese Medicine · ORCID：0000-0003-1384-5005

发表论文 59 篇 · 总被引 853 次 · h-index 14

代表论文

• A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro (2025 · Nature Communications · 被引 35)
• The current status and future of targeted-immune combination for hepatocellular carcinoma (2024 · Frontiers in Immunology · 被引 35)
• PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation (2024 · Cancer Letters · 被引 19)
• Global and China burden of hormone-related cancers and risk factors, 1990–2021: results from the Global Burden of Disease Study 2021 (2025 · BMC Public Health · 被引 6)
• Convertible ROS Nanocatalyst/Eliminator for Enhancing Tumor Radio‐Immunotherapy and Relieving Radiation Enteritis (2025 · Advanced Science · 被引 3)
• The pivotal role of mitochondria in the pathogenesis and treatment of liver failure: a comprehensive review (2026 · Molecular and Cellular Biochemistry · 被引 1)